
<!DOCTYPE article
  PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.4 20241031//EN" "JATS-archivearticle1-4-mathml3.dtd">
<article xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Front Pharmacol</journal-id><journal-id journal-id-type="pmc-domain-id">1524</journal-id><journal-id journal-id-type="pmc-domain">frontpharmacol</journal-id><journal-id journal-id-type="nlm-id">101548923</journal-id><journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id><journal-title-group><journal-title>Frontiers in Pharmacology</journal-title></journal-title-group><issn pub-type="epub">1663-9812</issn><?publisher_abbrev frontiers?><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC9341521</article-id><article-id pub-id-type="pmcid-ver">PMC9341521.1</article-id><article-id pub-id-type="pmcaid">9341521</article-id><article-id pub-id-type="pmcaiid">9341521</article-id><article-id pub-id-type="pmid">35924056</article-id><article-id pub-id-type="doi">10.3389/fphar.2022.925740</article-id><article-id pub-id-type="publisher-id">925740</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Pharmacology</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Role of 5HT1A Receptors in the Neuroprotective and Behavioral Effects of Cannabidiol in Hypoxic–Ischemic Newborn Piglets</article-title><alt-title alt-title-type="left-running-head">Barata et al.</alt-title><alt-title alt-title-type="right-running-head">CBD and 5HT1AR in Hypoxia–Ischemia</alt-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Barata</surname><given-names initials="L">Lorena</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>de Hoz-Rivera</surname><given-names initials="M">María</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Romero</surname><given-names initials="A">Angela</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Martínez</surname><given-names initials="M">María</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Silva</surname><given-names initials="L">Laura</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Villa</surname><given-names initials="M">María</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1785830/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Campa</surname><given-names initials="L">Leticia</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jiménez-Sánchez</surname><given-names initials="L">Laura</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1213902/overview"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Martínez-Orgado</surname><given-names initials="J">José</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="c001" ref-type="corresp">*</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/334561/overview"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>Servicio de Neonatología</institution>, <institution>Hospital Clínico San Carlos</institution>, <institution>IdISSC</institution>, <addr-line>Madrid</addr-line>, <country>Spain</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>Fundación para La Investigación Biomédica del Hospital Clínico San Carlos (IdISSC)</institution>, <addr-line>Madrid</addr-line>, <country>Spain</country>
</aff><aff id="aff3">
<sup>3</sup>
<institution>Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM)</institution>, <institution>Spanish National Research Council (CSIC)</institution>, <institution>Institut d'Investigacions Biomèdiques de Barcelona (IIBB)</institution>, <institution>Institut d'Investigacions August Pi i Sunyer (IDIBAPS)</institution>, <institution>ISCIII</institution>, <addr-line>Madrid</addr-line>, <country>Spain</country>
</aff><aff id="aff4">
<sup>4</sup>
<institution>Centro de Investigación Biomédica</institution>, <institution>Instituto de Biotecnoloía</institution>, <institution>Universidad de Granada</institution>, <addr-line>Granada</addr-line>, <country>Spain</country>
</aff><aff id="aff5">
<sup>5</sup>
<institution>Instituto de Investigación Biosanitaria de</institution>, <addr-line>Granada</addr-line>, <country>Spain</country>
</aff><author-notes><fn fn-type="edited-by"><p>
<bold>Edited by:</bold>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/386968/overview" ext-link-type="uri">Jorge Manzanares</ext-link>, Miguel Hernández University of Elche, Spain</p></fn><fn fn-type="edited-by"><p>
<bold>Reviewed by:</bold>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/982193/overview" ext-link-type="uri">Claudia Bregonzio</ext-link>, CCT CONICET Córdoba, Argentina</p><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/516654/overview" ext-link-type="uri">Manuel Narvaez Peláez</ext-link>, University of Malaga, Spain</p></fn><corresp id="c001">*Correspondence: José Martínez-Orgado, <email>jose.martinezo@salud.madrid.org</email>
</corresp><fn fn-type="other"><p>This article was submitted to Neuropharmacology, a section of the journal Frontiers in Pharmacology</p></fn></author-notes><pub-date pub-type="epub"><day>18</day><month>7</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>13</volume><issue-id pub-id-type="pmc-issue-id">400058</issue-id><elocation-id>925740</elocation-id><history><date date-type="received"><day>21</day><month>4</month><year>2022</year></date><date date-type="accepted"><day>30</day><month>5</month><year>2022</year></date></history><pub-history><event event-type="pmc-release"><date><day>18</day><month>07</month><year>2022</year></date></event><event event-type="pmc-live"><date><day>02</day><month>08</month><year>2022</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2022-08-04 15:17:56.240"><day>04</day><month>08</month><year>2022</year></date></event></pub-history><permissions><copyright-statement>Copyright © 2022 Barata, de Hoz-Rivera, Romero, Martínez, Silva, Villa, Campa, Jiménez-Sánchez and Martínez-Orgado.</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Barata, de Hoz-Rivera, Romero, Martínez, Silva, Villa, Campa, Jiménez-Sánchez and Martínez-Orgado</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fphar-13-925740.pdf"><?pdf-name fphar-13-925740.pdf?><?pdf-size 1264018?><?pdf-md5 642a48c5aee0f25c082ddb332db665b7?><?pdf-image-server-status NEVER_LOAD?><?pdf-cloudpmc-urn urn:app:2bc2/9341521/642a48c5aee0/fphar-13-925740.pdf?></self-uri><abstract><p>
<bold>Background:</bold> Hypoxic–ischemic (HI) insults have important deleterious consequences in newborns, including short-term morbidity with neuromotor and cognitive disturbances. Cannabidiol (CBD) has demonstrated robust neuroprotective effects and shows anxiolytic/antidepressant effects as well. These effects are thought to be related to serotonin 5-HT<sub>1A</sub> receptor (5HT<sub>1A</sub>R) activation. We hereby aimed to study the role of 5HT<sub>1A</sub>R in the neuroprotective and behavioral effects of CBD in HI newborn piglets.</p><p>
<bold>Methods:</bold> 1-day-old piglets submitted to 30 min of hypoxia (FiO2 10%) and bilateral carotid occlusion were then treated daily with vehicle, CBD 1 mg/kg, or CBD with the 5HT<sub>1A</sub>R antagonist WAY 100635 1 mg/kg 72 h post-HI piglets were studied using amplitude-integrated EEG to detect seizures and a neurobehavioral test to detect neuromotor impairments. In addition, behavioral performance including social interaction, playful activity, hyperlocomotion, and motionless periods was assessed. Then, brain damage was assessed using histology (Nissl and TUNEL staining) and biochemistry (proton magnetic resonance spectroscopy studies.</p><p>
<bold>Results:</bold> HI led to brain damage as assessed by histologic and biochemistry studies, associated with neuromotor impairment and increased seizures. These effects were not observed in HI piglets treated with CBD. These beneficial effects of CBD were not reversed by the 5HT<sub>1A</sub>R antagonist, which is in contrast with previous studies demonstrating that 5HT<sub>1A</sub>R antagonists eliminated CBD neuroprotection as assessed 6 h after HI in piglets. HI led to mood disturbances, with decreased social interaction and playfulness and increased hyperlocomotion. Mood disturbances were not observed in piglets treated with CBD, but in this case, coadministration of the 5HT<sub>1A</sub>R antagonist eliminates the beneficial effects of CBD.</p><p>
<bold>Conclusion:</bold> CBD prevented HI-induced mood disturbances in newborn piglets by acting on 5HT<sub>1A</sub>R. However, 5HT<sub>1A</sub>R activation seems to be necessary for CBD neuroprotection only in the first hours after HI.</p></abstract><kwd-group><kwd>hypoxia-ischemia</kwd><kwd>cannabidiol</kwd><kwd>serotonin receptors</kwd><kwd>neuroprotection</kwd><kwd>mood disorders</kwd><kwd>piglets</kwd></kwd-group><funding-group><award-group><funding-source id="cn001"><institution-wrap><institution>Instituto de Salud Carlos III
</institution><institution-id institution-id-type="doi">10.13039/501100004587</institution-id></institution-wrap></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1"><title>1 Introduction</title><p>Hypoxic–ischemic (HI) brain damage affects 1–3/1000 live-term newborns, representing one of the leading causes of death and permanent disability in infants (<xref rid="B27" ref-type="bibr">Zhou et al., 2020</xref>). The clinical picture of newborns with severe HI encephalopathy is that of deep coma, but newborns with mild-to-moderate HI encephalopathic show a varied neurologic picture that includes increased or decreased muscle tone and reflexes, fluctuating alertness, jitteriness, hyperexcitability, and seizures, depending on the timing and severity of the insult (<xref rid="B23" ref-type="bibr">Sarnat and Sarnat, 1976</xref>; <xref rid="B25" ref-type="bibr">Thompson et al., 1997</xref>). This situation makes the HI newborn particularly susceptible to the stress inherent in the application of the current standard of care and therapeutic hypothermia (<xref rid="B27" ref-type="bibr">Zhou et al., 2020</xref>), which determines that HI newborns under hypothermia very often receive sedatives as opioids (<xref rid="B5" ref-type="bibr">Berube et al., 2020</xref>). Since hypothermia affects the metabolism of opiates, opiate treatment during hypothermia easily causes unwanted side effects such as cardiorespiratory instability and neurologic depression (<xref rid="B5" ref-type="bibr">Berube et al., 2020</xref>).</p><p>Since hypothermia does not benefit a substantial number of HI newborns, additional or alternative neuroprotective strategies are being investigated (<xref rid="B27" ref-type="bibr">Zhou et al., 2020</xref>). Cannabidiol, the noneuphoric component of <italic toggle="yes">Cannabis sativa</italic>, has demonstrated robust neuroprotective effects in different models of HI brain damage in newborns, modulating inflammation, excitotoxicity, and oxidative stress, thus protecting neurons and glial cells (<xref rid="B17" ref-type="bibr">Martínez-Orgado et al., 2021</xref>). Although the mechanisms of action of CBD are not fully understood, it is known that CBD acts on different signaling pathways by activating different receptors such as the peroxisome proliferator-activated receptor gamma (PPARγ), G protein-coupled receptor 55 (GPR5), transient receptor potential vanilloid subtype 1 (TRPV1), and serotonin (5-hydroxytryptamine, 5-HT) 5-HT<sub>1A</sub> receptors (<xref rid="B8" ref-type="bibr">de Almeida and Devi, 2020</xref>; <xref rid="B24" ref-type="bibr">Silvestro et al., 2020</xref>; <xref rid="B17" ref-type="bibr">Martínez-Orgado et al., 2021</xref>; <xref rid="B18" ref-type="bibr">Melas et al., 2021</xref>). In fact, the main neuroprotective effects of CBD are believed to be related to the activation of the 5-HT<sub>1A</sub> receptor (5HT<sub>1A</sub>R) (<xref rid="B24" ref-type="bibr">Silvestro et al., 2020</xref>). This is interesting since CBD exerts modulatory effects on mood disturbances such as anxiety, panic, or depression mainly through the activation of 5HT<sub>1A</sub>R (<xref rid="B9" ref-type="bibr">De Gregorio et al., 2019</xref>; <xref rid="B8" ref-type="bibr">de Almeida and Devi, 2020</xref>; <xref rid="B18" ref-type="bibr">Melas et al., 2021</xref>). There are no reports on the effects of CBD on mood disturbances in newborn animals. We have reported that 5HT<sub>1A</sub>R blockade abolishes the neuroprotective effects of CBD in HI piglets as assessed 6 h after the insult, but in that study, piglets remained sedated, which together with the short follow-up time made it impossible to assess the effects of CBD and 5HT1AR blockers in the piglet behavior (<xref rid="B21" ref-type="bibr">Pazos et al., 2013</xref>).</p><p>The aim of this work was to study the involvement of 5HT1AR receptors on CBD neuroprotection and the effects of CBD in HI-induced mood disorders. For this, we used a model with high translational value, in which neuromotor and behavioral evaluations are carried out in HI piglets in addition to histological and biochemical studies (<xref rid="B14" ref-type="bibr">Lafuente et al., 2011</xref>; <xref rid="B4" ref-type="bibr">Barata et al., 2019b</xref>).</p></sec><sec id="s2"><title>2 Methods</title><sec id="s2-1"><title>2.1 Experimental Model</title><p>All procedures complied with European Directive (2010/63/EU) and Spanish (RD 53/2013) regulations for the protection of experimental animals and were approved by the Animal Welfare Ethics Committee of Hospital Clinico San Carlos in Madrid, Spain (ProEx 175/14). All experimental procedures were designed and carried out by personnel qualified in Laboratory Animal Science, following FELASA recommendations in categories B and C to reduce animal stress and enhance animal welfare. All surgery was performed under adequate anesthesia and analgesia, and great effort was made to minimize suffering and reduce the number of animals used. Furthermore, all experimental procedures on animal welfare (anesthesia and analgesia; drug and substance administration) and euthanasia of the animals were conducted in compliance with FELASA recommendations. The sample size was calculated accordingly and based on previous results experiments using the same model (<xref rid="B14" ref-type="bibr">Lafuente et al., 2011</xref>; <xref rid="B4" ref-type="bibr">Barata et al., 2019b</xref>).</p><sec id="s2-1-1"><title>2.1.1 Induction of Hypoxia–Ischemia</title><p>The protocol was based on the model reported extensively elsewhere (<xref rid="B14" ref-type="bibr">Lafuente et al., 2011</xref>; <xref rid="B4" ref-type="bibr">Barata et al., 2019b</xref>). In short, one-day-old male Landrace-White large piglets provided by a local certified farm the day the experiment started were intubated and then mechanically ventilated (Babylog8000, Dräger, Germany) under sevoflurane anesthesia (5% induction and 1% maintenance) and received morphine chloride 1 0.1 mg/kg I.M. A right jugular vein indwelling catheter was inserted and kept in place over the entire experimental period for i.v. drug administration. Nontraumatic stainless-steel wires were placed into the piglet head’s scalp to continuously monitor brain activity by amplitude-integrated electroencephalography (aEEG; BRM3, BrainZ Instruments, Auckland, New Zealand). Body temperature was maintained at 37.5–38.0°C by an air-warmed blanket. Piglets were then randomly assigned to the experimental group in a blind fashion. In the HI groups, each carotid artery was exposed and surrounded by an elastic band. Then, HI piglets underwent a 20-minute–long cerebral HI insult by interrupting carotid blood flow by pulling out the carotid bands and reducing inspired oxygen fraction (FiO<sub>2</sub>) to 10%. The 20-min countdown started when aEEG trace became flat. At the end of the HI period, the carotid flow was restored and FiO<sub>2</sub> increased to 21%. Piglets were similarly managed but without HI insult and were used as reference (sham group, SHM, <italic toggle="yes">n</italic> = 6).</p></sec><sec id="s2-1-2"><title>2.1.2 Drug Treatment</title><p>Thirty minutes after HI piglets were randomly assigned to receive i.v. vehicle (HV, <italic toggle="yes">n</italic> = 16) or CBD (Abcam, Cambridge, UK) 1 mg/k (HC, <italic toggle="yes">n</italic> = 15), alone or with the antagonist of serotonin 5HT<sub>1A</sub>R WAY100635 (Tocris Bioscience, Abingdon, UK) 1 mg/kg (HCW, <italic toggle="yes">n</italic> = 9). CBD was prepared in a 5 mg/ml formulation of ethanol : colliphor : saline at a ratio of 2 : 1 : 17 and further diluted in saline to administer a total volume of 10 ml by infusion pump over 10 min. WAY 100635 was administered 15 min before CBD and dissolved in the same vehicle. Doses of vehicle, CBD, and WAY 100635 were repeated every 24 h, three doses in total. Doses were selected following previous <italic toggle="yes">in vivo</italic> experiments by our group in HI piglets (<xref rid="B21" ref-type="bibr">Pazos et al., 2013</xref>; <xref rid="B3" ref-type="bibr">Barata et al., 2019a</xref>).</p></sec><sec id="s2-1-3"><title>2.1.3 Follow-Up</title><p>Then, after fully regaining consciousness from the experimental procedure and anesthesia, piglets were extubated and transferred to the animal care facility. Piglets were housed in stainless steel cages with 0.5 m<sup>2</sup> per animal in a well-controlled warm-temperature environment. The cage contained a pending rope and a plastic ball for environmental enrichment. From 24 h post-insult, piglets were fed with artificial piglet formula (Nutrilac Milk Replacer for young piglets, Joosten Products B.V. Weert, Netherlands) every 3-4 h by a catheter attached to the examiner’s finger to assess suckling. The examiner was blinded to the experimental group. Ceftazidime 15 mg/kg i.v. was administered every 12 h to prevent infections and acetaminophen 15 mg/kg i.v. was administered every 8 h for pain control. Seventy-two hours after the HI insult, piglets were sacrificed by KCl infusion under anesthesia (5% sevoflurane). Both carotid arteries were cannulated to perfuse brains with heparin in cold saline until clean fluid flew from the sectioned jugular arteries. Then, the brains were removed from the skull and sectioned. Brain slices from the left hemisphere were placed into 4% paraformaldehyde for histologic analysis, whereas those from the right hemisphere were snap frozen in isopentane and stored at −80°C for spectroscopy studies.</p></sec></sec><sec id="s2-2"><title>2.2 Neurobehavioral Assessment</title><p>Each morning from 8 to 10 a.m., the piglets were studied in the room where their cage was placed and video-recorded by one examiner. All video recordings were subsequently evaluated and scored when appropriate by three researchers blinded to the experimental group to obtain a mean value of the different items. A neurobehavioral score (NBS: 8–36 pts) (<xref rid="B14" ref-type="bibr">Lafuente et al., 2011</xref>; <xref rid="B4" ref-type="bibr">Barata et al., 2019b</xref>), based on that by LeBlanc et al. (<xref rid="B15" ref-type="bibr">LeBlanc et al., 1991</xref>), was carried out and video-recorded every 24 h, measuring alertness, behavior, muscle tone, standing, walking, and eating (<xref rid="T1" ref-type="table">Table 1</xref>).</p><table-wrap position="float" id="T1" orientation="portrait"><label>TABLE 1</label><caption><p>Neurobehavioral score (NBS).</p></caption><table frame="hsides" rules="groups"><tbody valign="top"><tr><td rowspan="4" align="left" colspan="1">
<italic toggle="yes">Mental status</italic>
</td><td align="left" rowspan="1" colspan="1">Coma</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Stupor</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Lethargy</td><td align="center" rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">Awake</td><td align="center" rowspan="1" colspan="1">4</td></tr><tr><td rowspan="4" align="left" colspan="1">
<italic toggle="yes">Behavior</italic>
</td><td align="left" rowspan="1" colspan="1">None</td><td align="char" char="." rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Weak</td><td align="char" char="." rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Aggressive</td><td align="char" char="." rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">Normal</td><td align="char" char="." rowspan="1" colspan="1">4</td></tr><tr><td rowspan="3" align="left" colspan="1">
<italic toggle="yes">Pupils</italic>
</td><td align="left" rowspan="1" colspan="1">Nonreactive</td><td align="char" char="." rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Slow, asymmetric</td><td align="char" char="." rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">Normal</td><td align="char" char="." rowspan="1" colspan="1">3</td></tr><tr><td rowspan="3" align="left" colspan="1">
<italic toggle="yes">Vestibulo–ocular reflex</italic>
</td><td align="left" rowspan="1" colspan="1">Absent Nystagmus</td><td align="char" char="." rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Normal</td><td align="char" char="." rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1">3</td></tr><tr><td rowspan="3" align="left" colspan="1">
<italic toggle="yes">Stepping</italic> (<italic toggle="yes">barrow</italic>)</td><td align="left" rowspan="1" colspan="1">None</td><td align="char" char="." rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Just fore/hind paws</td><td align="char" char="." rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">Normal</td><td align="char" char="." rowspan="1" colspan="1">3</td></tr><tr><td rowspan="2" align="left" colspan="1">
<italic toggle="yes">Righting</italic>
</td><td rowspan="2" align="left" colspan="1">Absent/present</td><td align="char" char="." rowspan="1" colspan="1">1</td></tr><tr><td align="char" char="." rowspan="1" colspan="1">2</td></tr><tr><td rowspan="4" align="left" colspan="1">
<italic toggle="yes">Muscle tone</italic>
</td><td align="left" rowspan="1" colspan="1">Atonic/hypertonic</td><td align="char" char="." rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Partially atonic</td><td align="char" char="." rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">Partially hypertonic</td><td align="char" char="." rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">Normal</td><td align="char" char="." rowspan="1" colspan="1">4</td></tr><tr><td rowspan="4" align="left" colspan="1">
<italic toggle="yes">Standing</italic>
</td><td align="left" rowspan="1" colspan="1">No</td><td align="char" char="." rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Paresis</td><td align="char" char="." rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">Unsteady</td><td align="char" char="." rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">Normal</td><td align="char" char="." rowspan="1" colspan="1">4</td></tr><tr><td rowspan="4" align="left" colspan="1">
<italic toggle="yes">Walking</italic>
</td><td align="left" rowspan="1" colspan="1">No</td><td align="char" char="." rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Paresis</td><td align="char" char="." rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">Falling</td><td align="char" char="." rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">Normal</td><td align="char" char="." rowspan="1" colspan="1">4</td></tr><tr><td rowspan="5" align="left" colspan="1">
<italic toggle="yes">Eating</italic>
</td><td align="left" rowspan="1" colspan="1">No suckling reflex</td><td align="char" char="." rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Weak reflex, tube feeding</td><td align="char" char="." rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">No appetite</td><td align="char" char="." rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">Brief suckling</td><td align="char" char="." rowspan="1" colspan="1">4</td></tr><tr><td align="left" rowspan="1" colspan="1">Normal</td><td align="char" char="." rowspan="1" colspan="1">5</td></tr></tbody></table></table-wrap><p>Piglets were also video recorded during free wandering for 5 min. According to previous studies (<xref rid="B4" ref-type="bibr">Barata et al., 2019b</xref>), time spent interacting with caretakers (following caretaker’s movements, pushing, nosing, sniffing, and licking) was considered social interaction time, whereas time spent in playful behavior (pushing, nosing, sniffing, and biting) with some known object (the sheet used for feeding) considered playfulness time. Time spent in unpurposive quick movements was considered hyperactivity time. Time with no activity while standing and lasting more than 5 s was considered motionless time. After the neurobehavioral assessment, piglets were wrapped up with a blanket and held by an examiner who sat in front of the aEEG device, to assess cerebral activity for over 10 min. Test start time and time when the piglet stopped fighting against immobilization (FAI) were recorded. The time of restlessness during slight restraint for aEEG performance was considered an indicator of piglet anxiety.</p></sec><sec id="s2-3"><title>2.3 Seizures</title><p>Raw EEG traces were manually reviewed for electric seizures (periods of rhythmic activity starting with a sudden increase in voltage of at least 2 μV, accompanied by a narrowing of the band of aEEG activity, lasting at least 15 s).</p></sec><sec id="s2-4"><title>2.4 Histologic Analysis</title><p>Histological studies were performed in 4 µm thick coronal sections obtained from fixed brain hemispheres, as reported previously (<xref rid="B14" ref-type="bibr">Lafuente et al., 2011</xref>; <xref rid="B21" ref-type="bibr">Pazos et al., 2013</xref>; <xref rid="B4" ref-type="bibr">Barata et al., 2019b</xref>). Areas of 1 mm<sup>2</sup> in the central three lobes of the parietal cortex and the adjacent CA1 area of the hippocampus were examined by two skilled investigators blinded to the experimental group. Neuronal necrosis was identified by Nissl staining, according to previous studies (<xref rid="B14" ref-type="bibr">Lafuente et al., 2011</xref>; <xref rid="B21" ref-type="bibr">Pazos et al., 2013</xref>; <xref rid="B4" ref-type="bibr">Barata et al., 2019b</xref>). Cell death was further studied in the cortex by TUNEL staining (DeadEnd Colorimetric TUNEL System, Promega, Spain) as reported elsewhere (<xref rid="B14" ref-type="bibr">Lafuente et al., 2011</xref>; <xref rid="B21" ref-type="bibr">Pazos et al., 2013</xref>; <xref rid="B4" ref-type="bibr">Barata et al., 2019b</xref>). Samples were visualized and photographed with a confocal TCS SP5 confocal microscope (Leica Microsystems, Wetzlar, Germany).</p></sec><sec id="s2-5"><title>2.5 Proton Magnetic Resonance Spectroscopy (<sup>1</sup>H-NMR)</title><p>
<italic toggle="yes">Ex vivo</italic>
<sup>1</sup>H spectrum was performed on a Bruker Avance 11.7 T spectrometer (Bruker BioSpin, Karlsruhe, Germany) equipped with a 4 mm triple channel 1H/13C/31P HR-MAS (High-Resolution Magic Angle Spinning) resonance probe. HMRS was performed in the MRI Unit of Instituto Investigaciones biomédicas “Alberto Sols” (CSIC-UAM, Madrid, Spain). Frozen cortex samples (5-10 mg weight) were introduced into a 50 µL zirconia rotor (4 mm OD) with 50 µL D2O and spun at 5000 Hz at 4°C to prevent tissue degradation processes. Two types of monodimensional proton spectra were acquired using water suppressed spin echo Carr Purcell Meiboom Gill (CPMG) sequence with 36 and 144 ms echo time and 128 scans. Data were collected into 64k data points using a spectral width of 10 kHz (20ppm) and water presaturation during a relaxation delay of 2 s, total acquisition of 16 min. All spectra were analyzed using the LC Model software; only peak concentrations obtained with a standard deviation lower than 20% were accepted. The content of glutamate (Glu), lactate (Lac), and N-acetylaspartate (NAA) was normalized to the creatine content.</p></sec><sec id="s2-6"><title>2.6 Brain Neurotransmitter Concentration</title><p>Brain concentration of norepinephrine (NE), dopamine (DA), and serotonin (5-HT) was measured in homogenate from frozen brain tissue by high-performance liquid chromatography (<xref rid="B4" ref-type="bibr">Barata et al., 2019b</xref>). In short, tissues were ultrasonically homogenized in 0.4 M perchloric acid with 5 mM sodium metabisulfite, 8.3 uM cysteine, and 0.3 mM of EDTA. Samples were then centrifuged at 12,000 g for 30 min at 4°C. The three neurotransmitters were separated using an Ultrasphere 3 µm column (7.5 cm × 0.46 cm, Beckman, San Ramon, CA) and detected with a Hewlett–Packard amperometric detector (Palo Alto, CA). The mobile phase comprised 0.15 M KH2PO4, 0.46 mM octyl sodium sulfate, 0.5 Mm EDTA (pH 2.8 adjusted with phosphoric acid), and 12% methanol and was pumped at a rate of 0.6 ml/min.</p></sec><sec id="s2-7"><title>2.7 Statistical Analysis</title><p>Data were analyzed with a statistical software package (GraphPad Prism 9.1.0; GraphPad Software, San Diego, CA, United States ). After assessing the normality of data distribution using the Shapiro–Wilk test, data showing normal distribution were displayed as mean ± SEM and compared using one-way ANOVA with Holm–Šidák’s test for multiple comparisons. Data showing a nonnormal distribution were displayed as median (CI 95%) and compared using Kruskall–Wallis with Dunn`s test for multiple comparisons. The distribution of qualitative parameters was studied using the <italic toggle="yes">X</italic>
<sup>2</sup> test. <italic toggle="yes">p</italic> &lt; 0.05 was considered significant.</p></sec></sec><sec id="s3"><title>3 Results</title><sec id="s3-1"><title>3.1 General Data</title><p>Piglets from all groups were similar in weight at the moment of the study (1.70 ± 0.1, 1.73 ± 0.1, 1.69 ± 0.1, and 1.78 ± 0.1 kg for SHM, HV, HC, and HCW, respectively, <italic toggle="yes">p</italic> = 0.83). Four out of 16 HV, three out of 15 HC, and one out of nine HCW piglets died in the first 24 h after HI (X<sup>2</sup> = 0.69, <italic toggle="yes">p</italic> = 0.7). This represents a mortality of 27.5%, similar to that reported (<xref rid="B14" ref-type="bibr">Lafuente et al., 2011</xref>; <xref rid="B4" ref-type="bibr">Barata et al., 2019b</xref>). None of the SHM piglets died during the follow-up.</p><p>WAY100635 exerted no demonstrable effects on SHM or vehicle-treated HI animals in all studies. Therefore, those piglets were not included in the final data analysis.</p></sec><sec id="s3-2"><title>3.2 Assessment of HI-Induced Brain Damage</title><p>HI led to a reduction in the density of viable neurons in the cortex and hippocampus, as assessed by Nissl staining and induced a dramatic increase in the number of TUNEL+ cells (<xref rid="F1" ref-type="fig">Figure 1A</xref>). Such effects of HI were not observed in CBD-treated piglets, which showed viable neuron and TUNEL+ cell density similar to SHM (<xref rid="F1" ref-type="fig">Figure 1B</xref>). Coadministration of the 5HT<sub>1A</sub>R blocker did not modify the protective effects of CBD (<xref rid="F1" ref-type="fig">Figures 1A, B</xref>).</p><fig position="float" id="F1" orientation="portrait"><label>FIGURE 1</label><caption><p>Brain damage assessment 72 h after hypoxic–ischemic insult in brain samples from piglets treated with vehicle (HV), cannabidiol (HC), and WAY 100635 (HCW). Non-hypoxic–ischemic piglets served as controls (SHM). <bold>(A)</bold> Representative microphotographs (<italic toggle="yes">left</italic>) and quantification (<italic toggle="yes">right</italic>) of viable neurons using Nissl staining in the temporoparietal cortex and adjacent CA1 area of the hippocampus. <bold>(B)</bold> Representative microphotographs (<italic toggle="yes">left</italic>) and quantification (<italic toggle="yes">right</italic>) of cell death using TUNEL staining. Bars represent the mean (SEM) of 6–12 experiments. Scale bar: 100 µm. <bold>(C)</bold> Results from proton magnetic resonance spectroscopy. Lac: lactate. Glu: glutamate. NAA: N-acetylaspartate. Boxes represent the median (IQR) and Whiskers' maximum and minimum values. (*) <italic toggle="yes">p</italic> &lt; 0.05 vs. SHM and (#) <italic toggle="yes">p</italic> &lt; 0.05 vs. HV by ANOVA with Holm–Šidack test for multiple comparisons <bold>(A, B)</bold> or Kruskall–Wallis with Dunn’s test for multiple comparisons <bold>(C)</bold>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fphar-13-925740-g001.jpg"><?image-name fphar-13-925740-g001.jpg?><?image-size 178818?><?image-md5 41cbb5607bccacf7961c285f6f0bf0f9?><?image-image-server-status LOAD_COMPLETED?><?image-original-height 1865?><?image-original-width 1295?><?image-scaled-height 932?><?image-scaled-width 647?><?image-cloudpmc-urn urn:cdn:blobs/2bc2/9341521/41cbb5607bcc/fphar-13-925740-g001.jpg?><?thumb-name fphar-13-925740-g001.gif?><?thumb-size 17263?><?thumb-md5 3b24298e7b060a46b9467fdaec83ba01?><?thumb-image-server-status NEVER_LOAD?><?thumb-scaled-height 144?><?thumb-scaled-width 100?><?thumb-cloudpmc-urn urn:cdn:blobs/2bc2/9341521/3b24298e7b06/fphar-13-925740-g001.gif?></graphic></fig><p>HI insult led to brain metabolic derangement, as reflected by the increase in Lac/NAA ratio in the <sup>1</sup>H-NMR studies (<xref rid="F1" ref-type="fig">Figure 1C</xref>). In addition, HI led to increased excitotoxicity as reflected by the higher Glu/NAA ratio in HI than in SHM animals (<xref rid="F1" ref-type="fig">Figure 1C</xref>). Lac/NAA and Glu/NAA increase was not observed in HI piglets treated with CBD (<xref rid="F1" ref-type="fig">Figure 1C</xref>). Coadministration of the 5HT<sub>1A</sub>R blocker did not modify the protective effects of CBD (<xref rid="F1" ref-type="fig">Figure 1C</xref>).</p></sec><sec id="s3-3"><title>3.3 Seizures</title><p>The aEEG exam revealed electric seizures 72 h after HI in four out of 12 HV piglets but in none of the SHM, HC, or HCW piglets (<italic toggle="yes">X</italic>
<sup>2</sup> = 8.65, <italic toggle="yes">p</italic> = 0.03). The seizure burden in those piglets was 17.9 ± 6.8 (1.4–32.5% of the recording time).</p></sec><sec id="s3-4"><title>3.4 Functional and Behavioral Studies</title><p>HI insult led to a decrease in NBS global score 72 h after HI in HV animals (<xref rid="T2" ref-type="table">Table 2</xref>). Such a decrease was because of the decrease in motor and behavioral scores and in eating proficiency (<xref rid="T2" ref-type="table">Table 2</xref>). Such impairments were not observed in HC animals, which showed an NBS global score similar to SHM animals (<xref rid="T2" ref-type="table">Table 2</xref>). HCW animals showed a trend of worse behavioral and eating performance, but this did not reach statistical significance (<xref rid="T2" ref-type="table">Table 2</xref>).</p><table-wrap position="float" id="T2" orientation="portrait"><label>TABLE 2</label><caption><p>Neurobehavioral assessment.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">SHM (n = 6)</th><th align="center" rowspan="1" colspan="1">HI + VEH (<italic toggle="yes">n</italic> = 12)</th><th align="center" rowspan="1" colspan="1">HI + CBD (<italic toggle="yes">n</italic> = 12)</th><th align="center" rowspan="1" colspan="1">HI + CBD + WAY (<italic toggle="yes">n</italic> = 8)</th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="1" colspan="1">Conscience</td><td align="center" rowspan="1" colspan="1">4.0 (4.0, 4.0)</td><td align="center" rowspan="1" colspan="1">4.0 (3.6, 4.1)</td><td align="center" rowspan="1" colspan="1">4.0 (4.0, 4.0)</td><td align="center" rowspan="1" colspan="1">4.0 (4.0, 4.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Behavior</td><td align="center" rowspan="1" colspan="1">4.0 (3.6, 4.1)</td><td align="center" rowspan="1" colspan="1">3.0 (1.7, 3,3)*</td><td align="center" rowspan="1" colspan="1">4.0 (3.3, 4.1)<sup>#</sup>
</td><td align="center" rowspan="1" colspan="1">3.5 (2.8, 3.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Pupils</td><td align="center" rowspan="1" colspan="1">3.0 (3.0, 3.0)</td><td align="center" rowspan="1" colspan="1">3.0 (3.0, 3.0)</td><td align="center" rowspan="1" colspan="1">3.0 (3.0, 3.0)</td><td align="center" rowspan="1" colspan="1">3.0 (3.0, 3.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">VOR</td><td align="center" rowspan="1" colspan="1">3.0 (3.0, 3.0)</td><td align="center" rowspan="1" colspan="1">3.0 (3.0, 3.0)</td><td align="center" rowspan="1" colspan="1">3.0 (3.0, 3.0)</td><td align="center" rowspan="1" colspan="1">3.0 (3.0, 3.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Barrow</td><td align="center" rowspan="1" colspan="1">3.0 (3.0,3 0.0)</td><td align="center" rowspan="1" colspan="1">3.0 (1.8, 3.1)</td><td align="center" rowspan="1" colspan="1">3.0 (2.7, 3.0)</td><td align="center" rowspan="1" colspan="1">3.0 (2.7, 3.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Righting</td><td align="center" rowspan="1" colspan="1">2.0 (2.0, 2.0)</td><td align="center" rowspan="1" colspan="1">2.0 (1.3, 2.1)</td><td align="center" rowspan="1" colspan="1">2.0 (2.0, 2.0)</td><td align="center" rowspan="1" colspan="1">2.0 (2.0, 2.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Tone</td><td align="center" rowspan="1" colspan="1">4.0 (4.0, 4.0)</td><td align="center" rowspan="1" colspan="1">3.2 (1.9, 3.6)*</td><td align="center" rowspan="1" colspan="1">4.0 (3.6, 4.0)</td><td align="center" rowspan="1" colspan="1">4.0 (3.6, 4.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Standing</td><td align="center" rowspan="1" colspan="1">4.0 (4.0, 4.0)</td><td align="center" rowspan="1" colspan="1">3.7 (2.2, 4.1)</td><td align="center" rowspan="1" colspan="1">4.0 (3.5, 3.9)</td><td align="center" rowspan="1" colspan="1">4.0 (3.6, 4.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Walking</td><td align="center" rowspan="1" colspan="1">4.0 (4.0, 4.0)</td><td align="center" rowspan="1" colspan="1">3.5 (2.2, 4.0)</td><td align="center" rowspan="1" colspan="1">4.0 (3.6, 4.0)</td><td align="center" rowspan="1" colspan="1">3.7 (3.5, 3.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Eating</td><td align="center" rowspan="1" colspan="1">5.0 (4.3, 5.3)</td><td align="center" rowspan="1" colspan="1">4.0 (2.2, 4.4)*</td><td align="center" rowspan="1" colspan="1">5.0 (4.5, 5.0)<sup>#</sup>
</td><td align="center" rowspan="1" colspan="1">4.0 (3.4, 4.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">Total</td><td align="center" rowspan="1" colspan="1">36.0 (35.1, 36.2)</td><td align="center" rowspan="1" colspan="1">31.5 (23.6, 34.5)*</td><td align="center" rowspan="1" colspan="1">35.5 (33.8, 35.8)<sup>#</sup>
</td><td align="center" rowspan="1" colspan="1">34.0 (32.7, 34.7)</td></tr></tbody></table><table-wrap-foot><fn><p>Median (CI, 95%). SHM: sham. HI<bold>:</bold> hypoxia–ischemia. VEH: vehicle. CBD: cannabidiol. WAY: WAY, 100635. VOR: vestibulo–ocular reflex. (∗) <italic toggle="yes">p</italic> &lt; 0.05 vs. SHM, and (#) <italic toggle="yes">p</italic> &lt; 0.05 vs. HV, by ANOVA, with Holm–Šidack test for multiple comparisons.</p></fn></table-wrap-foot></table-wrap><p>HI led to mood disturbances in piglets as observed in HV piglets 72 h after HI. HV piglets showed increased anxiety as reflected by a nearly twofold increase in the FAI time (<xref rid="F2" ref-type="fig">Figure 2A</xref>). In HV piglets there was a reduction in social interaction and playful activity (<xref rid="F2" ref-type="fig">Figures 2B, C</xref>). By contrast, HV piglets showed increased hyperactivity time and increased motionless time (<xref rid="F2" ref-type="fig">Figures 2D, E</xref>). Mood disturbances were not observed in HI piglets treated with CBD. Thus, playfulness, social interaction, hyperactivity, and motionless time, and FAI time, were similar in HC and SHM animals (<xref rid="F2" ref-type="fig">Figures 2A–E</xref>). In this case, coadministration of the 5HT<sub>1A</sub>R antagonist abolished the protective effects of CBD, with HCW showing similar responses to those of HV animals (<xref rid="F2" ref-type="fig">Figures 2A–E</xref>)</p><fig position="float" id="F2" orientation="portrait"><label>FIGURE 2</label><caption><p>Neurobehavioral assessment 72 h after hypoxic–ischemic insult in piglets treated with vehicle (HV), cannabidiol (HC), and WAY 100635 (HCW). Non-hypoxic–ischemic piglets served as controls (SHM). <bold>(A)</bold> Time spent fighting against immobilization (FAI) (<italic toggle="yes">left</italic>). Relative time (<italic toggle="yes">right</italic>) spent in <bold>(B)</bold> social interaction, <bold>(C)</bold> playfulness, <bold>(D)</bold> hyperlocomotion, and <bold>(E)</bold> motionless periods. Bars represent the mean (SEM) of 6–12 experiments. (∗) <italic toggle="yes">p</italic> &lt; 0.05 vs. SHM and (#) <italic toggle="yes">p</italic> &lt; 0.05 vs. HV by ANOVA with Holm–Šidack test for multiple comparisons.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fphar-13-925740-g002.jpg"><?image-name fphar-13-925740-g002.jpg?><?image-size 84700?><?image-md5 02c057339e008f57035d16f079014eed?><?image-image-server-status LOAD_COMPLETED?><?image-original-height 1909?><?image-original-width 968?><?image-scaled-height 1272?><?image-scaled-width 645?><?image-cloudpmc-urn urn:cdn:blobs/2bc2/9341521/02c057339e00/fphar-13-925740-g002.jpg?><?thumb-name fphar-13-925740-g002.gif?><?thumb-size 10588?><?thumb-md5 f3b3dae3a823448d85b106022642c04b?><?thumb-image-server-status NEVER_LOAD?><?thumb-scaled-height 197?><?thumb-scaled-width 100?><?thumb-cloudpmc-urn urn:cdn:blobs/2bc2/9341521/f3b3dae3a823/fphar-13-925740-g002.gif?></graphic></fig></sec><sec id="s3-5"><title>3.5 Monoamine Brain Concentration</title><p>There was an increase in NE, DA, and 5HT concentration in brain samples obtained from HV animals 72 h after HI (<xref rid="F3" ref-type="fig">Figures 3A–C</xref>). Such an increase was prevented by CBD administration, with HC animals showing similar monoamine brain concentration similar to SHM (<xref rid="F3" ref-type="fig">Figures 3A–C</xref>). Coadministration of the 5HT<sub>1A</sub>R blocker did not modify the protective effects of CBD (<xref rid="F3" ref-type="fig">Figures 3A–C</xref>).</p><fig position="float" id="F3" orientation="portrait"><label>FIGURE 3</label><caption><p>Brain monoamine concentration 72 h after hypoxic–ischemic insult in brain samples from piglets treated with vehicle (HV), cannabidiol (HC), and WAY 100635 (HCW). Non-hypoxic–ischemic piglets served as controls (SHM). Boxes represent the median (IQR) and Whiskers' maximum and minimum values of brain concentration of <bold>(A)</bold> norepinephrine (NE), <bold>(B)</bold> dopamine (A), and <bold>(C)</bold> 5-hydroxytriptamine (5-HT). (∗) <italic toggle="yes">p</italic> &lt; 0.05 vs. SHM and (#) <italic toggle="yes">p</italic> &lt; 0.05 vs. HV by Kruskall–Wallis with Dunn’s test for multiple comparisons.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fphar-13-925740-g003.jpg"><?image-name fphar-13-925740-g003.jpg?><?image-size 92839?><?image-md5 c3c60118628c83dd05d1985ba2b239b3?><?image-image-server-status LOAD_COMPLETED?><?image-original-height 1631?><?image-original-width 495?><?image-scaled-height 1631?><?image-scaled-width 495?><?image-cloudpmc-urn urn:cdn:blobs/2bc2/9341521/c3c60118628c/fphar-13-925740-g003.jpg?><?thumb-name fphar-13-925740-g003.gif?><?thumb-size 14652?><?thumb-md5 804b0d0871e44c379665515edbc2f1f3?><?thumb-image-server-status NEVER_LOAD?><?thumb-scaled-height 329?><?thumb-scaled-width 100?><?thumb-cloudpmc-urn urn:cdn:blobs/2bc2/9341521/804b0d0871e4/fphar-13-925740-g003.gif?></graphic></fig></sec></sec><sec id="s4"><title>4 Discussion</title><p>HI insult led to brain damage in newborn piglets as assessed 72 h after the insult. HI led to the reduction in the cortex of viable neurons in Nissl-stained preparations and increased TUNEL positive cells, increased Lac/NAA ratio in <sup>1</sup>H-NMR studies, increased seizures, and the development of neuromotor deficits, as has been described (<xref rid="B4" ref-type="bibr">Barata et al., 2019b</xref>). All these features were not observed in piglets treated with CBD at a daily dose of 1 mg/kg for 3 days. The beneficial histological and neuromotor effects of CBD evaluated 72 h after HI insults in piglets have also been described after administering a single dose of CBD (<xref rid="B14" ref-type="bibr">Lafuente et al., 2011</xref>).</p><sec id="s4-1"><title>4.1 5HT<sub>1A</sub>R Antagonism Did Not Affect CBD Neuroprotective Effects</title><p>In this work, the neuroprotective effects of CBD evaluated 72 h after HI were not affected by the coadministration of 5HT<sub>1A</sub>R antagonist. However, we have reported that coadministration of the same 5HT<sub>1A</sub>R antagonist results in loss of CBD neuroprotection assessed 6 h after a HI insult in piglets (<xref rid="B21" ref-type="bibr">Pazos et al., 2013</xref>). CBD is a well-known allosteric agonist of 5HT<sub>1A</sub>R (<xref rid="B22" ref-type="bibr">Russo et al., 2005</xref>; <xref rid="B8" ref-type="bibr">de Almeida and Devi, 2020</xref>; <xref rid="B24" ref-type="bibr">Silvestro et al., 2020</xref>; <xref rid="B18" ref-type="bibr">Melas et al., 2021</xref>). It is generally accepted that the main neuroprotective effects of CBD are related to 5HT<sub>1A</sub>R activation (<xref rid="B24" ref-type="bibr">Silvestro et al., 2020</xref>). Our results suggest that this is the case for CBD neuroprotection in the brain of newborn piglets in the first hours after HI, but later, CBD could exert neuroprotective actions by mechanisms independent of 5HT<sub>1A</sub>R activation. Although other mechanisms were not studied in this work, it has been widely described that CBD can induce neuroprotective effects by activating other receptors such as PPARγ, GPR55, and TRPV1, increasing brain neurotrophic factor (BDNF) expression, modulating adenosine activity, or exerting antioxidant actions related to its molecular structure (<xref rid="B20" ref-type="bibr">Mori et al., 2017</xref>; <xref rid="B8" ref-type="bibr">de Almeida and Devi, 2020</xref>; <xref rid="B24" ref-type="bibr">Silvestro et al., 2020</xref>; <xref rid="B17" ref-type="bibr">Martínez-Orgado et al., 2021</xref>; <xref rid="B18" ref-type="bibr">Melas et al., 2021</xref>). 5HT<sub>1A</sub>R agonists are neuroprotective in different preclinical models of HI brain damage in adult animals (<xref rid="B2" ref-type="bibr">Aguiar et al., 2021</xref>). It is unlikely that the signaling cascade triggered by 5HT<sub>1A</sub>R activation was operational 6 h but not 72 h after HI insult in piglet brains. Indeed, 5HT<sub>1A</sub>R activation was involved in the neurobehavioral effects of CBD in piglets 72 h after HI, as discussed below, suggesting that 5HT<sub>1A</sub>R were operational at that time. Due to this finding, it is also unlikely that 5HT<sub>1A</sub>R activation was less relevant in CBD neuroprotection due to a dramatic reduction of 5HT<sub>1A</sub>R density. A mild reduction of 5HT<sub>1A</sub>R density in the striatum, related to greater destruction of serotoninergic neurons, is described 7 days after HI insults in P3 rats, which present a brain developmental status similar to that of premature infants (<xref rid="B6" ref-type="bibr">Buller et al., 2012</xref>). In contrast, the 5HT<sub>1A</sub>R expression is upregulated in P7 rats, which present a brain developmental status similar to that of term infants, 7 days after HI insult (<xref rid="B10" ref-type="bibr">Franco et al., 2019</xref>). In addition, the reduction of 5HT<sub>1A</sub>R in P3 rats is associated with a decrease in the brain concentration of 5HT (<xref rid="B6" ref-type="bibr">Buller et al., 2012</xref>), an effect not observed in our experiments. However, since we did not directly study either 5HT<sub>1A</sub>R-related signaling pathways or 5HT<sub>1A</sub>R density in the brain, these considerations remain speculative and deserve further study. In a preclinical model of stroke in adult mice, CBD neuroprotection is related to increased regional and intralesional cerebral blood flow, an effect that is dependent on 5HT<sub>1A</sub>R activation (<xref rid="B19" ref-type="bibr">Mishima et al., 2005</xref>). It is conceivable that such an effect on cerebral blood flow would be more important in the first few hours after HI, when cerebral blood flow is dramatically reduced (<xref rid="B12" ref-type="bibr">Hassell et al., 2015</xref>); however, the relevance of this effect would be much less once brain hypoperfusion evolves into hyperperfusion and then to the normalization of cerebral blood flow (<xref rid="B12" ref-type="bibr">Hassell et al., 2015</xref>). More studies are needed, however, to demonstrate that the lack of effect of 5HT<sub>1A</sub>R antagonism on CBD neuroprotection would also be observable in brain areas not explored in our work such as the striatum, cerebellum, or white matter.</p></sec><sec id="s4-2"><title>4.2 HI Insult Led to Mood Disturbances in Piglets</title><p>The HI insult also caused behavioral disturbances in the piglets. Although the NBS includes the item “behavior,” its qualitative nature makes it subjective and highly dependent on the examiner’s skills. The additional behavioral assessment that we performed, based on some basic behavioral characteristics of piglets such as playfulness, social interaction, and anxiety responses to immobilization, obtains quantitative and objective parameters (<xref rid="B4" ref-type="bibr">Barata et al., 2019b</xref>). HI led to mood disturbances in piglets, as evidenced by reduced social interaction and playtime with objects, suggestive of less attention and/or motivation, and by hyperactivity alternating with motionless episodes. This picture was associated with a greater anxious response during restraint. These features, which are related to brain damage in HI piglets (<xref rid="B4" ref-type="bibr">Barata et al., 2019b</xref>), mimic some presence in human newborns two-to-three days after mild-to-moderate HI brain insults, such as jitteriness and attention deficits (<xref rid="B23" ref-type="bibr">Sarnat and Sarnat, 1976</xref>; <xref rid="B25" ref-type="bibr">Thompson et al., 1997</xref>). We found that mood disturbances coincided with increased brain levels of monoamines such as NE, DA, and 5HT. Increased brain concentration of NE, DA, and 5HT is observed in the brain of adult Wistar rats that develop hypertonia after transient global brain ischemia and is attributed to increased release due to cell destruction along with reduced reuptake due to energy failure (<xref rid="B11" ref-type="bibr">Globus et al., 1992</xref>). In piglets, there is a transient increase in brain concentration of the DA transporter in the first days after HI, which is thought to correspond with increased DA levels, related to the damage of dopaminergic neurons in the striatum (<xref rid="B26" ref-type="bibr">Zhang et al., 2012</xref>). In our work, hyperlocomotion and anxious response to stress could be attributed to increased DA concentration in the brain (<xref rid="B16" ref-type="bibr">Liu et al., 2018</xref>), but motionless and reduced playfulness are more suggestive of depression-like behavior (<xref rid="B13" ref-type="bibr">Kanitz et al., 2004</xref>) that is not an effect of increased monoamine concentration (<xref rid="B16" ref-type="bibr">Liu et al., 2018</xref>). These features suggest that mood disturbances observed in HI piglets were due to a dysregulation of monoaminergic networks due to brain damage rather than to a direct effect of increased monoamine concentration in the brain. In addition, depressive behavior is linked to reduced BDNF levels in mice brains after acute ischemic insults (<xref rid="B20" ref-type="bibr">Mori et al., 2017</xref>), although this was not explored in our work.</p></sec><sec id="s4-3"><title>4.3 5HT<sub>1A</sub>R Antagonism Modified CBD Effects on Mood Disturbances After HI</title><p>CBD treatment prevented the development of mood disturbances in piglets after HI. In this case, coadministration of the 5HT<sub>1A</sub>R antagonist eliminated the protective effect of CBD. CBD is a well-known anxiolytic substance (<xref rid="B8" ref-type="bibr">de Almeida and Devi, 2020</xref>; <xref rid="B18" ref-type="bibr">Melas et al., 2021</xref>) that also shows antidepressant effects (<xref rid="B1" ref-type="bibr">Abame et al., 2021</xref>). These effects are mediated by 5HT<sub>1A</sub>R (<xref rid="B9" ref-type="bibr">De Gregorio et al., 2019</xref>; <xref rid="B8" ref-type="bibr">de Almeida and Devi, 2020</xref>). At 100 mg/kg, CBD can increase 5HT concentration in rat brain (<xref rid="B1" ref-type="bibr">Abame et al., 2021</xref>), but at 5 mg/kg, the antipanic effect of CBD is reversed by 5HT<sub>1A</sub>R antagonists, and it is not associated with changes in the concentration of 5HT (<xref rid="B7" ref-type="bibr">Campos et al., 2013</xref>). In our case, the CBD dose was even lower than that. Furthermore, the concentration of 5HT in the brain of CBD-treated HI piglets was similar to that of SHM animals, whereas the effects of CBD on mood disturbances disappeared after 5HT<sub>1A</sub>R blockade. The modulatory effects of CBD on brain monoamine concentration after HI were not reversed by 5HT<sub>1A</sub>R blockage. A similar effect on glutamate release was observed, with an increase in Glu/NAA ratio as assessed by <sup>1</sup>H-NMR studies in HV but not in HC or HCW animals. These data suggest that the modulatory effects of CBD on neurotransmitter release were not due to a direct effect on 5HT<sub>1A</sub>R. CBD is known to reduce the release of neurotransmitter (<xref rid="B8" ref-type="bibr">de Almeida and Devi, 2020</xref>; <xref rid="B24" ref-type="bibr">Silvestro et al., 2020</xref>; <xref rid="B17" ref-type="bibr">Martínez-Orgado et al., 2021</xref>; <xref rid="B18" ref-type="bibr">Melas et al., 2021</xref>). But in our case, it could also be the result of the general neuroprotective effects of CBD. Furthermore, CBD normalizes BDNF expression in the mouse brain after hypoxic–ischemic insults, an effect that explains the antidepressant effects of CBD in this condition (<xref rid="B20" ref-type="bibr">Mori et al., 2017</xref>).</p><p>Taken together, these results support the idea that the effect of CBD on mood disturbances in HI piglets was elicited by direct activation of 5HT<sub>1A</sub>R. Interestingly, in our study CBD prevented the appearance of mood disturbances at a dose of 1 mg/kg. In preclinical studies in adult rodents, anxiolytic or antidepressant effects of acute CBD administration are generally obtained at doses of 2.5 mg/kg or higher, although anxiolytic effects as observed in social interaction tests have been reported for CBD 1 mg/kg in mice (<xref rid="B18" ref-type="bibr">Melas et al., 2021</xref>). The robust effects we observed with such a low dose of CBD suggest that an immature brain would be particularly sensitive to 5HT<sub>1A</sub>R agonism by CBD. We have described in the brain of immature rats that HI insults lead to increased expression and signaling of 5HT<sub>1A</sub>R in the first days after HI, an effect of greater magnitude in newborns than in adult rats (<xref rid="B10" ref-type="bibr">Franco et al., 2019</xref>).</p><p>In conclusion, HI insult led to brain damage in newborn piglets, as observed in histological and biochemistry studies 72 h after HI. At that time, brain damage was associated with increased seizures, and neuromotor deficits, and behavioral disorders, including mood disturbances such as reduced social interaction and playfulness and increased anxiety and hyperactivity. Postinsult CBD administration prevented HI-induced brain damage, and neuromotor deficits and behavioral disturbances. Coadministration of the 5HT<sub>1A</sub>R antagonist WAY 100635 did not modify the beneficial effects of CBD on brain damage and neuromotor performance. This is in contrast to previous studies demonstrating that 5HT1AR blockade abolishes CBD neuroprotection assessed 6 h after HI, suggesting that 5HT1AR activation plays a critical role in CBD neuroprotection only in the first moments after HI. Further studies to determine more precisely the time point after which 5HT1AR antagonism no longer reverses the protective effects of CBD are warranted. In contrast, 5HT1AR blockade eliminated the beneficial effects of CBD on HI-induced mood disturbances, suggesting that these effects were related to 5HT1AR activation. These results indicate that, in addition to its robust neuroprotective effects, CBD could be an interesting candidate to be included in the treatment of HI newborns to mitigate the consequences of stress derived from brain damage and hypothermia treatment.</p></sec></sec></body><back><ack><p>We are indebted to Carlos Vargas for excellent technical assistance.</p></ack><sec sec-type="data-availability" id="s5"><title>Data Availability Statement</title><p>The raw data supporting the conclusion of this article will be made available by the authors, without undue reservation, upon request to the corresponding author.</p></sec><sec id="s6"><title>Ethics Statement</title><p>The animal study was reviewed and approved by the Ethics Committee for Animal Welfare of Hospital Clinico San Carlos-IdISSC. Written informed consent was obtained from the owners for the participation of their animals in this study.</p></sec><sec id="s7"><title>Author Contributions</title><p>LJ-S and JM-O contributed to the conception and design of the study. LB and JM-O performed the experiments and the neuromotor and neurobehavioral studies and organized the database. MH-R, AR, MM, LS, and MV performed the biochemical and histological studies and interpreted the neuromotor, behavioral, and spectroscopy studies. LJ-S and LC performed de HPL studies. JM-O performed the statistical analysis, wrote the first draft of the manuscript, and edited the final version of the manuscript. All authors contributed to manuscript revision and read and approved the submitted version.</p></sec><sec id="s8"><title>Funding</title><p>This work was supported by the PI19/00927 project, integrated with the Plan National de I + D + I, AES 2017-2020, funded by the ISCIII and cofunded by the European Regional Development Fund (ERDF) “A way to make Europe”.</p></sec><sec sec-type="COI-statement" id="s9"><title>Conflict of Interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="disclaimer" id="s10"><title>Publisher’s Note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><sec id="s11"><title>Supplementary Material</title><p>The Supplementary Material for this article can be found online at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.frontiersin.org/articles/10.3389/fphar.2022.925740/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fphar.2022.925740/full#supplementary-material</ext-link>
</p><supplementary-material id="SM1" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="DataSheet1.PDF" position="float" orientation="portrait"><?suppdata-name DataSheet1.PDF?><?suppdata-size 60647?><?suppdata-md5 481fd1ef4060567ae62b8f3e1c0f1736?><?suppdata-image-server-status NEVER_LOAD?><?suppdata-mime-type application?><?suppdata-mime-sub-type pdf?><?suppdata-cloudpmc-urn urn:app:2bc2/9341521/481fd1ef4060/DataSheet1.PDF?><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Abame</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Chronic Administration of Synthetic Cannabidiol Induces Antidepressant Effects Involving Modulation of Serotonin and Noradrenaline Levels in the hippocampus</article-title>. <source>Neurosci. Lett.</source>
<volume>744</volume>, <fpage>135594</fpage>. <pub-id pub-id-type="doi">10.1016/j.neulet.2020.135594</pub-id>
<pub-id pub-id-type="pmid">33388355</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Aguiar</surname><given-names>R. P. d.</given-names></name><name name-style="western"><surname>Newman-Tancredi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Prickaerts</surname><given-names>J.</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>R. M. W. d.</given-names></name></person-group> (<year>2021</year>). <article-title>The 5-HT1A Receptor as a Serotonergic Target for Neuroprotection in Cerebral Ischemia</article-title>. <source>Prog. Neuro-Psychopharmacology Biol. Psychiatry</source>
<volume>109</volume>, <fpage>110210</fpage>. <pub-id pub-id-type="doi">10.1016/j.pnpbp.2020.110210</pub-id>
<pub-id pub-id-type="pmid">33333136</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Barata</surname><given-names>L.</given-names></name><name name-style="western"><surname>Arruza</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rodríguez</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Aleo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vierge</surname><given-names>E.</given-names></name><name name-style="western"><surname>Criado</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2019a</year>). <article-title>Neuroprotection by Cannabidiol and Hypothermia in a Piglet Model of Newborn Hypoxic-Ischemic Brain Damage</article-title>. <source>Neuropharmacology</source>
<volume>146</volume>, <fpage>1</fpage>–<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2018.11.020</pub-id>
<pub-id pub-id-type="pmid">30468796</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Barata</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cabañas</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lafuente</surname><given-names>H.</given-names></name><name name-style="western"><surname>Vargas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ceprián</surname><given-names>M.</given-names></name><name name-style="western"><surname>Campa</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2019b</year>). <article-title>aEEG and Neurologic Exam Findings Correlate with Hypoxic-Ischemic Brain Damage Severity in a Piglet Survival Model</article-title>. <source>Pediatr. Res.</source>
<volume>85</volume>, <fpage>539</fpage>–<lpage>545</lpage>. <pub-id pub-id-type="doi">10.1038/s41390-019-0282-2</pub-id>
<pub-id pub-id-type="pmid">30675020</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Berube</surname><given-names>M. W.</given-names></name><name name-style="western"><surname>Lemmon</surname><given-names>M. E.</given-names></name><name name-style="western"><surname>Pizoli</surname><given-names>C. E.</given-names></name><name name-style="western"><surname>Bidegain</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tolia</surname><given-names>V. N.</given-names></name><name name-style="western"><surname>Cotten</surname><given-names>C. M.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Opioid and Benzodiazepine Use during Therapeutic Hypothermia in Encephalopathic Neonates</article-title>. <source>J. Perinatol.</source>
<volume>40</volume>, <fpage>79</fpage>–<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1038/S41372-019-0533-4</pub-id>
<pub-id pub-id-type="pmid">31616049</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Buller</surname><given-names>K. M.</given-names></name><name name-style="western"><surname>Wixey</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Reinebrant</surname><given-names>H. E.</given-names></name></person-group> (<year>2012</year>). <article-title>Disruption of the Serotonergic System after Neonatal Hypoxia-Ischemia in a Rodent Model</article-title>. <source>Neurol. Res. Int.</source>
<volume>2012</volume>, <fpage>650382</fpage>. <pub-id pub-id-type="doi">10.1155/2012/650382</pub-id>
<pub-id pub-id-type="pmid">22474587</pub-id><pub-id pub-id-type="pmcid">PMC3306961</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Campos</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Ortega</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Palazuelos</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fogaça</surname><given-names>M. V.</given-names></name><name name-style="western"><surname>Aguiar</surname><given-names>D. C.</given-names></name><name name-style="western"><surname>Díaz-Alonso</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>The Anxiolytic Effect of Cannabidiol on Chronically Stressed Mice Depends on Hippocampal Neurogenesis: Involvement of the Endocannabinoid System</article-title>. <source>Int. J. Neuropsychopharmacol.</source>
<volume>16</volume>, <fpage>1407</fpage>–<lpage>1419</lpage>. <pub-id pub-id-type="doi">10.1017/S1461145712001502</pub-id>
<pub-id pub-id-type="pmid">23298518</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>de Almeida</surname><given-names>D. L.</given-names></name><name name-style="western"><surname>Devi</surname><given-names>L. A.</given-names></name></person-group> (<year>2020</year>). <article-title>Diversity of Molecular Targets and Signaling Pathways for CBD</article-title>. <source>Pharmacol. Res. Perspect.</source>
<volume>8</volume>, <fpage>e00682</fpage>. <pub-id pub-id-type="doi">10.1002/prp2.682</pub-id>
<pub-id pub-id-type="pmid">33169541</pub-id><pub-id pub-id-type="pmcid">PMC7652785</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>De Gregorio</surname><given-names>D.</given-names></name><name name-style="western"><surname>McLaughlin</surname><given-names>R. J.</given-names></name><name name-style="western"><surname>Posa</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ochoa-Sanchez</surname><given-names>R.</given-names></name><name name-style="western"><surname>Enns</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lopez-Canul</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Cannabidiol Modulates Serotonergic Transmission and Reverses Both Allodynia and Anxiety-like Behavior in a Model of Neuropathic Pain</article-title>. <source>Pain</source>
<volume>160</volume>, <fpage>136</fpage>–<lpage>150</lpage>. <pub-id pub-id-type="doi">10.1097/j.pain.0000000000001386</pub-id>
<pub-id pub-id-type="pmid">30157131</pub-id><pub-id pub-id-type="pmcid">PMC6319597</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Franco</surname><given-names>R.</given-names></name><name name-style="western"><surname>Villa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Morales</surname><given-names>P.</given-names></name><name name-style="western"><surname>Reyes-Resina</surname><given-names>I.</given-names></name><name name-style="western"><surname>Gutiérrez-Rodríguez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jiménez</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Increased Expression of Cannabinoid CB2 and Serotonin 5-HT1A Heteroreceptor Complexes in a Model of Newborn Hypoxic-Ischemic Brain Damage</article-title>. <source>Neuropharmacology</source>
<volume>152</volume>, <fpage>58</fpage>–<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2019.02.004</pub-id>
<pub-id pub-id-type="pmid">30738036</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Globus</surname><given-names>M. Y.</given-names></name><name name-style="western"><surname>Wester</surname><given-names>P.</given-names></name><name name-style="western"><surname>Busto</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dietrich</surname><given-names>W. D.</given-names></name></person-group> (<year>1992</year>). <article-title>Ischemia-induced Extracellular Release of Serotonin Plays a Role in Ca1 Neuronal Cell Death in Rats</article-title>. <source>Stroke</source>
<volume>23</volume>, <fpage>1595</fpage>–<lpage>1601</lpage>. <pub-id pub-id-type="doi">10.1161/01.STR.23.11.1595</pub-id>
<pub-id pub-id-type="pmid">1279842</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Hassell</surname><given-names>K. J.</given-names></name><name name-style="western"><surname>Ezzati</surname><given-names>M.</given-names></name><name name-style="western"><surname>Alonso-Alconada</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hausenloy</surname><given-names>D. J.</given-names></name><name name-style="western"><surname>Robertson</surname><given-names>N. J.</given-names></name></person-group> (<year>2015</year>). <article-title>New Horizons for Newborn Brain Protection: Enhancing Endogenous Neuroprotection</article-title>. <source>Arch. Dis. Child. Fetal Neonatal Ed.</source>
<volume>100</volume>, <fpage>F541</fpage>–<lpage>F552</lpage>. <pub-id pub-id-type="doi">10.1136/archdischild-2014-306284</pub-id>
<pub-id pub-id-type="pmid">26063194</pub-id><pub-id pub-id-type="pmcid">PMC4680177</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kanitz</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tuchscherer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Puppe</surname><given-names>B.</given-names></name><name name-style="western"><surname>Tuchscherer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Stabenow</surname><given-names>B.</given-names></name></person-group> (<year>2004</year>). <article-title>Consequences of Repeated Early Isolation in Domestic Piglets (<italic toggle="yes">Sus scrofa</italic>) on Their Behavioural, Neuroendocrine, and Immunological Responses</article-title>. <source>Brain. Behav. Immun.</source>
<volume>18</volume>, <fpage>35</fpage>–<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1016/S0889-1591(03)00085-0</pub-id>
<pub-id pub-id-type="pmid">14651945</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Lafuente</surname><given-names>H.</given-names></name><name name-style="western"><surname>Alvarez</surname><given-names>F. J.</given-names></name><name name-style="western"><surname>Pazos</surname><given-names>M. R.</given-names></name><name name-style="western"><surname>Alvarez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rey-Santano</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>Mielgo</surname><given-names>V.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Cannabidiol Reduces Brain Damage and Improves Functional Recovery after Acute Hypoxia-Ischemia in Newborn Pigs</article-title>. <source>Pediatr. Res.</source>
<volume>70</volume>, <fpage>272</fpage>–<lpage>277</lpage>. <pub-id pub-id-type="doi">10.1203/PDR.0b013e3182276b11</pub-id>
<pub-id pub-id-type="pmid">21654550</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>LeBlanc</surname><given-names>M. H.</given-names></name><name name-style="western"><surname>Vig</surname><given-names>V.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>B.</given-names></name><name name-style="western"><surname>Parker</surname><given-names>C. C.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>O. B.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>E. E.</given-names></name></person-group> (<year>1991</year>). <article-title>MK-801 Does Not Protect against Hypoxic-Ischemic Brain Injury in Piglets</article-title>. <source>Stroke</source>
<volume>22</volume>, <fpage>1270</fpage>–<lpage>1275</lpage>. <pub-id pub-id-type="doi">10.1161/01.STR.22.10.1270</pub-id>
<pub-id pub-id-type="pmid">1926238</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>W.</given-names></name></person-group> (<year>2018</year>). <article-title>Emotional Roles of Mono-Aminergic Neurotransmitters in Major Depressive Disorder and Anxiety Disorders</article-title>. <source>Front. Psychol.</source>
<volume>9</volume>, <fpage>2201</fpage>. <pub-id pub-id-type="doi">10.3389/FPSYG.2018.02201</pub-id>
<pub-id pub-id-type="pmid">30524332</pub-id><pub-id pub-id-type="pmcid">PMC6262356</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Martínez-Orgado</surname><given-names>J.</given-names></name><name name-style="western"><surname>Villa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Del Pozo</surname><given-names>A.</given-names></name></person-group> (<year>2021</year>). <article-title>Cannabidiol for the Treatment of Neonatal Hypoxic-Ischemic Brain Injury</article-title>. <source>Front. Pharmacol.</source>
<volume>11</volume>, <fpage>584533</fpage>. <pub-id pub-id-type="doi">10.3389/FPHAR.2020.584533</pub-id>
<pub-id pub-id-type="pmid">33505306</pub-id><pub-id pub-id-type="pmcid">PMC7830676</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Melas</surname><given-names>P. A.</given-names></name><name name-style="western"><surname>Scherma</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fratta</surname><given-names>W.</given-names></name><name name-style="western"><surname>Cifani</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fadda</surname><given-names>P.</given-names></name></person-group> (<year>2021</year>). <article-title>Cannabidiol as a Potential Treatment for Anxiety and Mood Disorders: Molecular Targets and Epigenetic Insights from Preclinical Research</article-title>. <source>Int. J. Mol. Sci.</source>
<volume>22</volume>, <fpage>1</fpage>–<lpage>15</lpage>. <pub-id pub-id-type="doi">10.3390/ijms22041863</pub-id>
<pub-id pub-id-type="pmcid">PMC7917759</pub-id><pub-id pub-id-type="pmid">33668469</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Mishima</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hayakawa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Abe</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ikeda</surname><given-names>T.</given-names></name><name name-style="western"><surname>Egashira</surname><given-names>N.</given-names></name><name name-style="western"><surname>Iwasaki</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Cannabidiol Prevents Cerebral Infarction via a Serotonergic 5-hydroxytryptamine1A Receptor-dependent Mechanism</article-title>. <source>Stroke</source>
<volume>36</volume>, <fpage>1077</fpage>–<lpage>1082</lpage>. <pub-id pub-id-type="doi">10.1161/01.STR.0000163083.59201.34</pub-id>
<pub-id pub-id-type="pmid">15845890</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Mori</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>E.</given-names></name><name name-style="western"><surname>Soares</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Milani</surname><given-names>H.</given-names></name><name name-style="western"><surname>Guimarães</surname><given-names>F. S.</given-names></name><name name-style="western"><surname>de Oliveira</surname><given-names>R. M. W.</given-names></name></person-group> (<year>2017</year>). <article-title>Cannabidiol Reduces Neuroinflammation and Promotes Neuroplasticity and Functional Recovery after Brain Ischemia</article-title>. <source>Prog. Neuropsychopharmacol. Biol. Psychiatry</source>
<volume>75</volume>, <fpage>94</fpage>–<lpage>105</lpage>. <pub-id pub-id-type="doi">10.1016/j.pnpbp.2016.11.005</pub-id>
<pub-id pub-id-type="pmid">27889412</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Pazos</surname><given-names>M. R.</given-names></name><name name-style="western"><surname>Mohammed</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lafuente</surname><given-names>H.</given-names></name><name name-style="western"><surname>Santos</surname><given-names>M.</given-names></name><name name-style="western"><surname>Martínez-Pinilla</surname><given-names>E.</given-names></name><name name-style="western"><surname>Moreno</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Mechanisms of Cannabidiol Neuroprotection in Hypoxic-Ischemic Newborn Pigs: Role of 5HT(1A) and CB2 Receptors</article-title>. <source>Neuropharmacology</source>
<volume>71</volume>, <fpage>282</fpage>–<lpage>291</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2013.03.027</pub-id>
<pub-id pub-id-type="pmid">23587650</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Russo</surname><given-names>E. B.</given-names></name><name name-style="western"><surname>Burnett</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>B.</given-names></name><name name-style="western"><surname>Parker</surname><given-names>K. K.</given-names></name></person-group> (<year>2005</year>). <article-title>Agonistic Properties of Cannabidiol at 5-HT1a Receptors</article-title>. <source>Neurochem. Res.</source>
<volume>30</volume>, <fpage>1037</fpage>–<lpage>1043</lpage>. <pub-id pub-id-type="doi">10.1007/s11064-005-6978-1</pub-id>
<pub-id pub-id-type="pmid">16258853</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Sarnat</surname><given-names>H. B.</given-names></name><name name-style="western"><surname>Sarnat</surname><given-names>M. S.</given-names></name></person-group> (<year>1976</year>). <article-title>Neonatal Encephalopathy Following Fetal Distress. A Clinical and Electroencephalographic Study</article-title>. <source>Arch. Neurol.</source>
<volume>33</volume>, <fpage>696</fpage>–<lpage>705</lpage>. <comment>Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/987769" ext-link-type="uri">http://www.ncbi.nlm.nih.gov/pubmed/987769</ext-link> (Accessed April 9, 2018)</comment>. <pub-id pub-id-type="doi">10.1001/archneur.1976.00500100030012</pub-id>
<pub-id pub-id-type="pmid">987769</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Silvestro</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schepici</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bramanti</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mazzon</surname><given-names>E.</given-names></name></person-group> (<year>2020</year>). <article-title>Molecular Targets of Cannabidiol in Experimental Models of Neurological Disease</article-title>. <source>Molecules</source>
<volume>25</volume>, <fpage>12</fpage>–<lpage>15</lpage>. <pub-id pub-id-type="doi">10.3390/molecules25215186</pub-id>
<pub-id pub-id-type="pmcid">PMC7664437</pub-id><pub-id pub-id-type="pmid">33171772</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Thompson</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Puterman</surname><given-names>A. S.</given-names></name><name name-style="western"><surname>Linley</surname><given-names>L. L.</given-names></name><name name-style="western"><surname>Hann</surname><given-names>F. M.</given-names></name><name name-style="western"><surname>Van Der Elst</surname><given-names>C. W.</given-names></name><name name-style="western"><surname>Molteno</surname><given-names>C. D.</given-names></name><etal/></person-group> (<year>1997</year>). <article-title>The Value of a Scoring System for Hypoxic Ischaemic Encephalopathy in Predicting Neurodevelopmental Outcome</article-title>. <source>Acta Paediatr.</source>
<volume>86</volume>, <fpage>757</fpage>–<lpage>761</lpage>. <pub-id pub-id-type="doi">10.1111/j.1651-2227.1997.tb08581.x</pub-id>
<pub-id pub-id-type="pmid">9240886</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y. F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X. Y.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Burns</surname><given-names>K.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Q. Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X. M.</given-names></name></person-group> (<year>2012</year>). <article-title>Simultaneously Changes in Striatum Dopaminergic and Glutamatergic Parameters Following Hypoxic-Ischemic Neuronal Injury in Newborn Piglets</article-title>. <source>Eur. J. Paediatr. Neurol.</source>
<volume>16</volume>, <fpage>271</fpage>–<lpage>278</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejpn.2011.05.010</pub-id>
<pub-id pub-id-type="pmid">21723167</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>K. Q.</given-names></name><name name-style="western"><surname>Davidson</surname><given-names>J. O.</given-names></name><name name-style="western"><surname>Bennet</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gunn</surname><given-names>A. J.</given-names></name></person-group> (<year>2020</year>). <article-title>Combination Treatments with Therapeutic Hypothermia for Hypoxic-Ischemic Neuroprotection</article-title>. <source>Dev. Med. Child. Neurol.</source>
<volume>62</volume>, <fpage>1131</fpage>–<lpage>1137</lpage>. <pub-id pub-id-type="doi">10.1111/dmcn.14610</pub-id>
<pub-id pub-id-type="pmid">32614467</pub-id></mixed-citation></ref></ref-list></back></article>